Quality of life and health-related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 6, 2010, Pages 674-678

  Poole, C D ^a   Chambers, C ^b   Allsopp, R ^b   Currie, C J ^c  

^a Pharmatelligence   (United Kingdom)

^b ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Atopic dermatitis; Corticosteroids; EQ5D; Health utility; Mapping; Quality of life; SF 12; SF 36; Tacrolimus ointment

Indexed keywords

CORTICOSTEROID; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; OINTMENT;

ADULT; ALGORITHM; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; TREATMENT RESPONSE; COST BENEFIT ANALYSIS; DERMATITIS, ATOPIC; ECONOMICS; OINTMENT; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; SEVERITY OF ILLNESS INDEX; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; UNITED KINGDOM;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ADULT; COST-BENEFIT ANALYSIS; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; DRUG UTILIZATION REVIEW; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; OINTMENTS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 77952188535     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03485.x     Document Type: Article

References (25)

1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Suppl) 1980 92 : 44 47.
2. Williams HC, Strachan DP. The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol 2003 139 : 834 839.
3. Gupta R, Sheikh A, Strachan DP, Anderson HR. Time trends in allergic disorders in the UK. Thorax 2007 62 : 91 96.
4. Simpson CR, Newton J, Hippisley-Cox J, Sheikh A. Trends in the epidemiology and prescribing of medication for eczema in England. J R Soc Med 2009 102 : 108 117.
5. Levy RM, Gelfand JM, Yan AC. The epidemiology of atopic dermatitis. Clin Dermatol 2003 21 : 109 115.
6. National Collaborating Centre for Women's and Children's Health. Atopic eczema in children (NICE Clinical Guideline No.57). RCOG Press, London, 2007. URL http://guidance.nice.org.uk/CG57/Guidance/pdf/English (last accessed: 22 October 2009).
7. NICE. Guide to the methods of technology appraisal (reference N0515). 2004. URL http://www.nice.org.uk/download.aspx?o=201973 (last accessed: 28 March 2009).
8. Haapasaari K-M, Risteli J, Oikarinen A. Recovery of human skin collagen synthesis after short-term topical corticosteroid treatment and comparison between young and old subjects. Br J Dermatol 1996 135 : 65 69.
9. Jablonska S, Groniowska M, Dabroswki J. Comparative evaluation of skin atrophy in man induced by topical corticoids. Br J Dermatol 1979 100 : 193 206.
10. Reitamo S, Rissanen J, Remitz A et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998 111 : 396 398.
11. Soter NA, Fleischer AB, Webster GF et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. Part II, safety. J Am Acad Dermatol 2001 44 : 39 46.
12. Hanifin JM, Ling MR, Langley R et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. Part I, efficacy. J Am Acad Dermatol 2001 44 : 28 38.
13. Peninsula Technology Assessment Group (PenTAG). The Effectiveness and Cost-Effectiveness of Pimecrolimus and Tacrolimus for Atopic Eczema. National Institute for Clinical Excellence, London, 2004. URL http://www.nice.org.uk/ nicemedia/pdf/Eczema-report-final.pdf (last accessed: 22 October 2009).
14. Hjelmgren J, Svensson A, Jorgensen ET, Lindemalm-Lundstam B, Ragnarson Tennvall G. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data. Br J Dermatol 2007 156 : 913 921.
15. Reitamo S, Ortonne JP, Sand C et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005 152 : 1282 1289.
16. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol (Stockh) 1989 144 (Suppl. 13 14.
17. Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health 1999 53 : 46 50.
18. Gray AM, Rivero-Arias O, Clarke PM. Estimating the association between SF-12 responses and EQ5D utility values by response mapping. Med Decis Making 2006 26 : 18.
19. Ware JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey : Construction of scales and preliminary tests of reliability and validity, Med Care 1996 34 : 220 233.
20. SPSS for Windows, Rel. 15.0.1. SPSS Inc.
21. Verstappen SM, Jacobs JW, van der Heijde DM et al. Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis. Ann Rheum Dis 2007 66 : 727 731.
22. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005 43 : 736 749.
23. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ5D and SF-6D. Qual Life Res 2005 14 : 1523 1532.
24. Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes 2003 1 : 4.
25. NHS Business Services Authority, Prescription Pricing Division. NHS Electronic Drug Tariff. NHS Business Services Authority, Prescription Pricing Division. 2009. URL http://www.ppa.org.uk/ppa/edt-intro.htm (last accessed: 2 February 2009).